The University of Ghana Medical School (UGMS) has dismissed claims circulating on social media that its researchers have developed a cassava-based compound capable of reversing Type 2 diabetes.
In a statement issued on Sunday, UGMS described the claims as “entirely false and misleading.”
It clarified that it has not conducted any research involving such a compound, popularly referred to online as “cassavarin,” nor has it undertaken any related clinical trials.
“The University of Ghana Medical School has not conducted any such study, has not isolated any compound by that name, and has not undertaken clinical trials of the nature described,” the statement said.
The institution further debunked assertions contained in the viral publication suggesting that the supposed discovery had received regulatory approval, attracted pharmaceutical industry lawsuits, or entered licensing negotiations.
“The claims regarding regulatory approvals, pharmaceutical lawsuits, and licensing are fabricated,” UGMS stated.
UGMS emphasiSed its commitment to rigorous scientific standards and ethical research practices, stressing that misinformation of this nature poses a risk to public health.
“The University of Ghana Medical School maintains the highest standards of scientific integrity and ethical research practice,” it noted.
The hospital advised members of the public to verify health-related information and rely solely on announcements released through official University of Ghana communication channels.
“Members of the public are advised to rely only on information released through official University of Ghana channels,” the statement added.
See the statement below:
